Opendata, web and dolomites

CHAMPION SIGNED

Cartilage Healing Approach Merging Polymer InnOvation with Nature

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CHAMPION project word cloud

Explore the words cloud of the CHAMPION project. It provides you a very rough idea of what is the project "CHAMPION" about.

liquid    gradually    situ    action    injury    entrance    mark    migration    cell    barrier    conforming    replaced    stem    acellular    resorbs    unlike    requiring    chondrocytes    implant    quick    limiting    ready    gained    arthroscopic    bone    treatments    successful    cells    optimizing    shelf    rate    treatment    ultraviolet    light    differentiate    market    excellence    optimal    designed    regulatory    microfracture    shape    polyethylene    replacement    defects    osteoarthritis    right    surgery    multiple    gelrinc    million    articular    interventions    painful    procedure    inwards    focal    ce    cartilage    undesired    pursuit    longterm    trials    knee    implantation    harnesses    poor    failed    time    resorbable    complexity    synchronized    afflicts    patients    joint    microenvironment    degradation    realized    off    symptomatic    stimulation    fibrinogen    limited    implants    frequent    re    completing    2017    outside    cured    denatured    promise    commercialization    annually    benefit    risks    preventing    body    outcome    human    alternative    clinical    elusive    total    centres    hyaline    channels    injuries    marrow    prochondrogenic    cellular    therapeutic    glycol    form    mode    defect    biologicals   

Project "CHAMPION" data sheet

The following table provides information about the project.

Coordinator
REGENTIS BIOMATERIALS LTD 

Organization address
address: HA ILAN STREET 2 NORTHERN INDUSTRIAL ZONE
city: OR AKIVA
postcode: 30600
website: www.regentis.co.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙121˙700 €
 EC max contribution 2˙185˙190 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGENTIS BIOMATERIALS LTD IL (OR AKIVA) coordinator 2˙185˙190.00

Map

 Project objective

Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process. GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials,improving the procedure towards arthroscopic implantation; and creating commercialization channels including centres of excellence in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHAMPION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHAMPION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More